Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Exchange Rate Effect (2018 - 2025)

Historic Exchange Rate Effect for Autolus Therapeutics (AUTL) over the last 8 years, with Q3 2025 value amounting to -$3.6 million.

  • Autolus Therapeutics' Exchange Rate Effect fell 10949.84% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.5 million, marking a year-over-year decrease of 16814.87%. This contributed to the annual value of -$261000.0 for FY2024, which is 10173.65% down from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Exchange Rate Effect is -$3.6 million, which was down 10949.84% from $5.7 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Exchange Rate Effect high stood at $37.7 million for Q3 2024, and its period low was -$38.2 million during Q4 2024.
  • For the 5-year period, Autolus Therapeutics' Exchange Rate Effect averaged around -$456368.4, with its median value being $1.3 million (2021).
  • The largest annual percentage gain for Autolus Therapeutics' Exchange Rate Effect in the last 5 years was 140994.55% (2022), contrasted with its biggest fall of 150255.26% (2022).
  • Autolus Therapeutics' Exchange Rate Effect (Quarter) stood at $734000.0 in 2021, then surged by 1409.95% to $11.1 million in 2022, then decreased by 11.82% to $9.8 million in 2023, then crashed by 491.04% to -$38.2 million in 2024, then soared by 90.62% to -$3.6 million in 2025.
  • Its Exchange Rate Effect was -$3.6 million in Q3 2025, compared to $5.7 million in Q2 2025 and $3.6 million in Q1 2025.